The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report
Open accessAbstract
Quantitative HBsAg had been suggested to be helpful in management of HBV, but assays were cumbersome. The recent availability of commercial quantitative assays has restarted the interest in quantitative serum hepatitis B surface antigen (HBsAg) as a biomarker for prognosis and treatment response in chronic hepatitis B. HBsAg level reflects the transcriptional activity of cccDNA rather than the absolute amount of cccDNA copies. Serum HBsAg level tends to be higher in hepatitis B e antigen (HBeAg)-positive than HBeAg-negative patients. Among patients with a low HBV DNA (<2000IU/ml), HBsAg <1000IU/ml in genotype D HBV infection and HBsAg <100IU/ml in genotype B/C HBV infection is associated with inactive carrier state in HBeAg-negative patients. The HBsAg reduction by nucleos(t)ide analogues (NA) is not as pronounced as by interferon treatment. On peginterferon treatment, sustained responders tend to show greater HBsAg decline than the non-responders. The optimal on-treatment HBsAg cutoff to predict response needs further evaluation in HBeAg-positive patients, but an absence of HBsAg decline together with a <2 log reduction in HBV DNA at week 12 can serve as stopping rule in HBeAg-negative patients with genotype D HBV infection. A rapid serum HBsAg decline during NA therapy may identify patients who will clear HBsAg in the long-term. There are early reports among Asian patients that an HBsAg level of <100IU/ml might predict lower risk of relapse after stopping NA treatment. In clinical practice, serum HBsAg level should be used together with, but not as a substitute for, HBV DNA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Singh, R. P., Kurz, J., & Boiteau, G. (1996) · Journal of Virological Methods · doi:10.1016/0166-0934(96)02096-4 · Cited by 2,552
Lai, C. L., Ratziu, V., Yuen, M.-F., & Poynard, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15108-2 · Cited by 1,727
EASL clinical practice guidelines management of chronic hepatitis B
张学武, & Li, X. (2009) · Inter J Epidemiol Infect Dis · doi:10.3760/cma.j.issn.1673-4149.2009.04.001 · Cited by 1,506
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.001 · Cited by 1,347
Marcellin, P., Lau, G. K. K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., Lu, Z.-M., Piratvisuth, T., Germanidis, G., Yurdaydin, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040431 · Cited by 1,145
Self-citationWerle–Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., Trepo, C., Marcellin, P., Goodman, Z., & Delaney IV, W. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.018 · Cited by 905
Self-citationThe natural history of chronic hepatitis B virus infection #
McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.22898 · Cited by 876
Management of hepatitis B: 2000—Summary of a workshop
Lok, A. S., Heathcote, E. J., & Hoofnagle, J. H. (2001) · Gastroenterology · doi:10.1053/gast.2001.24839 · Cited by 776
Moucari, R., Mackiewicz, V., Lada, O., Ripault, M.-P., Castelnau, C., Martinot-Peignoux, M., Dauvergne, A., Asselah, T., Boyer, N., Bedossa, P., et al. (2009) · Hepatology · doi:10.1002/hep.22744 · Cited by 468
Self-citationThree-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
Heathcote, E. J., Marcellin, P., Buti, M., Gane, E., De Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.011 · Cited by 462
Self-citation
Cited by
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Trépo, C., Chan, H. L. Y., & Lok, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60220-8 · Cited by 1,623
Self-citationAsian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
Liaw, Y.-F., Kao, J.-H., Piratvisuth, T., Chan, H. L. Y., Chien, R.-N., Liu, C.-J., Gane, E., Locarnini, S., Lim, S.-G., Han, K.-H., et al. (2012) · Hepatology International · doi:10.1007/s12072-012-9365-4 · Cited by 1,038
Self-citationMajor findings and recent advances in virus–like particle (VLP)-based vaccines
Mohsen, M. O., Zha, L., Cabral-Miranda, G., & Bachmann, M. F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.014 · Cited by 555
The role of quantitative hepatitis B surface antigen revisited
Cornberg, M., Wong, V. W.-S., Locarnini, S., Brunetto, M., Janssen, H. L. A., & Chan, H. L.-Y. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.009 · Cited by 372
Self-citation
Metadata
- Authors
- Chan, H. L.-Y., Thompson, A., Martinot-Peignoux, M., Piratvisuth, T., Cornberg, M., Brunetto, M. R., Tillmann, H. L., Kao, J.-H., Jia, J.-D., Wedemeyer, H., Locarnini, S., Janssen, H. L. A., & Marcellin, P.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 55
- Issue
- 5
- Pages
- 1121-1131
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2008643979
- Cited by
- 321
- References
- 42
- FWCI
- 26.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. https://app.cochat.ai/papers/10.1016/j.jhep.2011.06.006
- The paper
- Chan, H. L.-Y., Thompson, A., Martinot-Peignoux, M., Piratvisuth, T., Cornberg, M., Brunetto, M. R., Tillmann, H. L., Kao, J.-H., Jia, J.-D., Wedemeyer, H., Locarnini, S., Janssen, H. L. A., & Marcellin, P. (2011). Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2011.06.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.